Here’s what you should know.
1. SGS United Kingdom Limited issued the suspension.
2. GI Dynamics CEO and President Scott Schorer said in a release the suspension is not related to EndoBarrier’s safety and efficacy.
3. Mr. Schorer said the suspension does not require a recall.
“We are working swiftly to address issues within our quality management system that were detailed in a corrective action report from SGS,” he said.
4. EndoBarrier hired a chief compliance officer with experience in the area to address the nonconformance issues SGS identified.
5. EndoBarrier has shipped a “sufficient” inventory to physicians to maintain supply levels through the suspension.
More articles on gastroenterology:
Underwater colonoscopy more effective than air insufflation — 5 insights
Variations in billing for colonoscopies leave patients footing the bill — Unclear pricing practices cause confusion, create debt
4 things to know about the AGA’s new President Dr. Sheila Crowe
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
